Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 2610 - 2610
Abstract Background: Splanchnic venous thrombosis (SVT) encompasses thrombosis in the mesenteric, splenic or portal veins (with or without hepatic veins...
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 4257 - 4257
Abstract This study retrospectively evaluated 144 consecutive patients with unusual site thrombosis who referred to our Thrombosis Center between 2000 and...
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 4976 - 4976
Abstract AML patients early relapsing within 12 months, still represents an extremely poor prognosis setting. Cytogenetic and molecular data are not diagnostic...
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 5109 - 5109
Abstract BACKGROUND The incidence of non Hodgkin's lymphoma (NHL) increases with age, over one third of NHL cases involves elderly patients >70 years of age....
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3943 - 3943
Abstract In elderly AML the prognosis still remains poor and unchanged in the last decades, with only 10% long term OS. Aging is often synonymous of frailty,...
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 1806 - 1806
Abstract The management of patients with chronic myeloid leukemia (CML) during pregnancy is a matter of continuous debate. The introduction of the tyrosin...
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5433 - 5433
Abstract Anthracyclines (AC) still constitute the mainstay of the 1st line treatment in lymphoma: their use, however, is limited by the occurrence of Cardiac...
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 346 - 346
Abstract Background - Point mutations in the BCR-ABL kinase domain are associated with resistance to TKI therapy. The most recent (2013) European Leukemia Net...
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 1735 - 1735
Abstract Abstract 1735 Background: Essential Thrombocytemia (ET) is a myeloproliferative neoplasm characterized by increased risk of vascular events....
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 22 - 33
In a prospective, randomized trial, patients with polycythemia vera who had a hematocrit target of less than 45% had a significantly lower rate of...
RECURRENT THROMBOSIS | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | RISK-FACTOR | EFFICACY | WARFARIN | PREVENTION | ESSENTIAL THROMBOCYTHEMIA | LEUKOCYTOSIS | HEMATOCRIT | Cardiovascular Diseases - etiology | Follow-Up Studies | Humans | Middle Aged | Hematocrit | Phlebotomy | Polycythemia Vera - blood | Male | Thrombosis - epidemiology | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Polycythemia Vera - therapy | Janus Kinase 2 | Polycythemia Vera - complications | Thrombosis - etiology | Cardiovascular Diseases - mortality | Female | Hydroxyurea - therapeutic use | Aged | Control | Usage | Care and treatment | Causes of | Polycythemia vera | Diagnosis | Cardiovascular diseases | Risk factors | Clinical trials | Medical treatment | Mutation
RECURRENT THROMBOSIS | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | RISK-FACTOR | EFFICACY | WARFARIN | PREVENTION | ESSENTIAL THROMBOCYTHEMIA | LEUKOCYTOSIS | HEMATOCRIT | Cardiovascular Diseases - etiology | Follow-Up Studies | Humans | Middle Aged | Hematocrit | Phlebotomy | Polycythemia Vera - blood | Male | Thrombosis - epidemiology | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Polycythemia Vera - therapy | Janus Kinase 2 | Polycythemia Vera - complications | Thrombosis - etiology | Cardiovascular Diseases - mortality | Female | Hydroxyurea - therapeutic use | Aged | Control | Usage | Care and treatment | Causes of | Polycythemia vera | Diagnosis | Cardiovascular diseases | Risk factors | Clinical trials | Medical treatment | Mutation
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S313 - S314
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 3621 - 3621
Abstract Abstract 3621 Acute myeloid leukemia (AML) has a dismal prognosis in elderly population because of intrinsic chemoresistance and frailty of patients....
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 3072 - 3072
Abstract Abstract 3072 Thromboembolic disease (TE) is a major cause of morbidity and mortality in Essential Thrombocythemia (ET). Recently JAK2V617 mutational...
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 3953 - 3953
Abstract Abstract 3953 Oral bexarotene, a novel retinoid that selectively activates retinoid × receptors, is approved for the treatment of cutaneous...
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 43 - 43
Abstract Background. The availability of multiple tyrosine kinase inhibitors (TKIs) and precise molecular monitoring has dramatically changed the prognosis in...
Journal Article
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2228 - 2237
BACKGROUND Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid leukemia (CML), there is a...
tyrosine kinase inhibitors | chronic myeloid leukemia | fatigue | quality of life | nilotinib | REPORTED OUTCOMES | FREE SURVIVAL | PROGNOSTIC VALUE | CANCER | GENERAL-POPULATION | INTERFERON-ALPHA | ONCOLOGY | CLINICAL-TRIALS | IMATINIB | EUROPEAN-ORGANIZATION | Severity of Illness Index | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - psychology | Prospective Studies | Pyrimidines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Fatigue - etiology | Fatigue - psychology | Male | Treatment Outcome | Fatigue - diagnosis | Protein Kinase Inhibitors - adverse effects | Self Report - statistics & numerical data | Young Adult | Protein Kinase Inhibitors - administration & dosage | Pyrimidines - adverse effects | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Longitudinal Studies | Nilotinib | Dosage and administration | Chronic myeloid leukemia | Drug therapy | Analysis | Quality of life | Tyrosine | Therapy | Statistical analysis | Compliance | Myeloid leukemia | Leukemia | Fatigue | Patients | Confidence intervals | Diagnostic systems | Protein-tyrosine kinase | Cancer
tyrosine kinase inhibitors | chronic myeloid leukemia | fatigue | quality of life | nilotinib | REPORTED OUTCOMES | FREE SURVIVAL | PROGNOSTIC VALUE | CANCER | GENERAL-POPULATION | INTERFERON-ALPHA | ONCOLOGY | CLINICAL-TRIALS | IMATINIB | EUROPEAN-ORGANIZATION | Severity of Illness Index | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - psychology | Prospective Studies | Pyrimidines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Fatigue - etiology | Fatigue - psychology | Male | Treatment Outcome | Fatigue - diagnosis | Protein Kinase Inhibitors - adverse effects | Self Report - statistics & numerical data | Young Adult | Protein Kinase Inhibitors - administration & dosage | Pyrimidines - adverse effects | Aged, 80 and over | Quality of Life | Adult | Female | Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications | Longitudinal Studies | Nilotinib | Dosage and administration | Chronic myeloid leukemia | Drug therapy | Analysis | Quality of life | Tyrosine | Therapy | Statistical analysis | Compliance | Myeloid leukemia | Leukemia | Fatigue | Patients | Confidence intervals | Diagnostic systems | Protein-tyrosine kinase | Cancer
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3021 - 3021
Abstract Introduction: Bosutinib is a Src/Abl tyrosine kinase inhibitor (TKI) currently licensed for patients with Ph+ chronic-phase (CP), accelerated-phase...
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 44 - 44
Abstract Background. Many prognostic scores have been proposed for risk stratification of chronic myeloid leukemia (CML) patients: the Sokal is the oldest and...
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 458 - 458
Abstract BACKGROUND: In chronic phase (CP) chronic myeloid leukemia (CML) nilotinib showed better efficacy compared to imatinib. The higher rates of deep...
Journal Article
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2228 - 2237
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.